Judah Frommer
Stock Analyst at Morgan Stanley
(3.17)
# 983
Out of 4,818 analysts
183
Total ratings
58.65%
Success rate
4.96%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Assumes: Equal-Weight | $120 → $100 | $85.93 | +16.37% | 1 | Mar 20, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Overweight | $46 | $19.53 | +135.54% | 1 | Mar 20, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $6.84 | +75.44% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $8.90 | +169.66% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $25.50 | -13.73% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $3.44 | +74.42% | 2 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $17.49 | +77.24% | 1 | Nov 21, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $63.97 | +65.70% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $15.53 | +125.37% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.77 | +369.31% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $0.91 | +229.63% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $4.63 | +763.93% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.02 | +1,174.51% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $30.78 | -2.53% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $9.52 | +141.60% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $50.05 | -0.10% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $59.44 | +137.21% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.21 | +974.38% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.53 | +490.16% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $17.15 | +28.28% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.76 | +47.06% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $3.60 | +122.53% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $12.16 | +278.29% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $0.94 | +644.68% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $14.41 | +281.68% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $70.87 | -35.09% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $79.95 | -38.71% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $975.84 | -62.08% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $64.29 | -51.78% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $72.89 | +4.27% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $95.43 | +90.72% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $83.43 | +28.25% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $111.14 | -14.52% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $22.41 | -19.68% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $74.18 | +56.38% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $114.03 | -66.68% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $164.67 | -86.64% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $72.00 | -51.39% | 9 | Apr 29, 2020 |
Blueprint Medicines
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $120 → $100
Current: $85.93
Upside: +16.37%
Celldex Therapeutics
Mar 20, 2025
Initiates: Overweight
Price Target: $46
Current: $19.53
Upside: +135.54%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $6.84
Upside: +75.44%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $8.90
Upside: +169.66%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $25.50
Upside: -13.73%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $3.44
Upside: +74.42%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $17.49
Upside: +77.24%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $63.97
Upside: +65.70%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $15.53
Upside: +125.37%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.77
Upside: +369.31%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $0.91
Upside: +229.63%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $4.63
Upside: +763.93%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.02
Upside: +1,174.51%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $30.78
Upside: -2.53%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $9.52
Upside: +141.60%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $50.05
Upside: -0.10%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $59.44
Upside: +137.21%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.21
Upside: +974.38%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.53
Upside: +490.16%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $17.15
Upside: +28.28%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.76
Upside: +47.06%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $3.60
Upside: +122.53%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $12.16
Upside: +278.29%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $0.94
Upside: +644.68%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $14.41
Upside: +281.68%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $70.87
Upside: -35.09%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $79.95
Upside: -38.71%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $975.84
Upside: -62.08%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $64.29
Upside: -51.78%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $72.89
Upside: +4.27%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $95.43
Upside: +90.72%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $83.43
Upside: +28.25%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $111.14
Upside: -14.52%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $22.41
Upside: -19.68%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $74.18
Upside: +56.38%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $114.03
Upside: -66.68%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $164.67
Upside: -86.64%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $72.00
Upside: -51.39%